CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Cixutumumab +1 morebiological
Likely dose
Cixutumumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00781911
NCT00781911Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma

Eli Lilly and Company·interventional·Posted Oct 29, 2008·Updated Sep 20, 2019

In Brief

A Phase 2 clinical trial evaluating Cixutumumab and depot octreotide for Carcinoma and Neuroendocrine Tumors. Completed, enrolled 43 participants across 10 sites.

Detailed Summary

Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Neuroendocrine Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 29, 2008
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2011
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.7 years ago

Interventions

Cixutumumabbiological

Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.

depot octreotidedrug

Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.